Drug Price Trends for HYDROCODONE-HOMATROPINE

Average Pharmacy Cost for HYDROCODONE-HOMATROPINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HYDROCODONE-HOMATROPINE 5-1.5 MG TABLET	64950-0206-10	0.95279	EACH	2025-02-19
HYDROCODONE-HOMATROPINE SOLN	10702-0150-16	0.07955	ML	2025-02-19
HYDROCODONE-HOMATROPINE 5-1.5 MG TABLET	64950-0206-03	0.95279	EACH	2025-02-19
HYDROCODONE-HOMATROPINE SOLN	64950-0371-47	0.07955	ML	2025-02-19
HYDROCODONE-HOMATROPINE 5-1.5 MG TABLET	10702-0055-01	0.95279	EACH	2025-02-19
HYDROCODONE-HOMATROPINE 5-1.5 MG TABLET	10702-0055-03	0.95279	EACH	2025-02-19

Market Analysis and Price Projections for Hydrocodone-Homatropine

Introduction

Hydrocodone-homatropine is a combination medication used to treat cough and other respiratory symptoms. It combines hydrocodone, an opioid cough suppressant, with homatropine, an anticholinergic that helps to reduce the production of mucus. Here, we will delve into the market analysis and price projections for this medication.

Market Size and Growth

The global opioids market, which includes hydrocodone-homatropine, was valued at USD 5.4 billion in 2022 and is expected to grow at a CAGR of 3.7% from 2023 to 2032, reaching USD 7.7 billion by 2032[3].

Segment Analysis

The opioids market is segmented by product type, with hydrocodone being one of the key segments. Hydrocodone-containing products are among the most frequently prescribed opioids, particularly in the United States. In 2013, over 136.7 million prescriptions for hydrocodone-containing products were dispensed, although this number has been declining due to efforts to reduce opioid prescribing in response to the opioid crisis[4].

Regional Market Analysis

North America

North America, particularly the United States, dominates the opioids market. This region has seen significant regulatory changes and public health initiatives aimed at reducing opioid misuse. Despite these efforts, the demand for opioid medications, including hydrocodone-homatropine, remains high due to the prevalence of chronic pain conditions[3].

Other Regions

While North America leads the market, other regions such as Europe, Asia Pacific, and South America also contribute significantly. The growth in these regions is driven by increasing approval rates for opioid medications and the rising need for pain management solutions.

Drivers of Market Growth

Increasing Geriatric Population

The growing geriatric population is a significant driver of the opioids market. Older adults are more likely to suffer from chronic diseases such as cancer, arthritis, and cardiovascular diseases, which necessitate the use of opioid medications for pain management[3].

Rising Approval Rates

The increasing approval of new opioid medications by regulatory authorities, such as the U.S. Food and Drug Administration, is another key driver. For instance, the introduction of new formulations and generic versions of existing opioids has expanded treatment options and contributed to market growth[3].

Restraints and Challenges

Side Effects and Misuse

The misuse of opioid drugs, including hydrocodone-homatropine, is a major restraint on market growth. Side effects such as respiratory depression, especially in children, and the risk of addiction and overdose are significant concerns. Regulatory bodies have implemented various measures to curb misuse, which can impact prescription rates[2][4].

Price Projections

Current Pricing

The prices of hydrocodone-homatropine can vary depending on the pharmacy and location. However, prices generally start at around $16.94 for a standard prescription[5].

Future Trends

Given the ongoing efforts to manage opioid prescribing and the potential for new formulations and generic versions, prices may remain relatively stable or see modest increases. The introduction of new opioid medications and changes in regulatory policies can influence pricing dynamics.

Regulatory Environment

FDA Safety Communications

The FDA has issued safety communications regarding the use of hydrocodone in children and adolescents, which has led to a decline in prescriptions. For example, prescriptions for hydrocodone cough and cold medications declined by 75.7% from 2014 to 2019 following FDA safety communications[1].

Health Canada Guidelines

Health Canada has also updated guidelines to reflect the risks associated with hydrocodone use in children under 6 years of age, further impacting prescription rates in this age group[2].

Conclusion

The market for hydrocodone-homatropine is influenced by a combination of factors including the growing need for pain management, regulatory changes, and public health initiatives aimed at reducing opioid misuse. While the market is expected to grow, it will likely do so at a moderate pace due to the ongoing scrutiny and regulatory oversight.

Key Takeaways

• The global opioids market, including hydrocodone-homatropine, is projected to grow at a CAGR of 3.7% from 2023 to 2032.
• North America, particularly the United States, dominates the market.
• The increasing geriatric population and rising approval rates for new opioid medications are key drivers of market growth.
• Regulatory measures and concerns over side effects and misuse are significant restraints.
• Prices are expected to remain relatively stable or see modest increases.

FAQs

What is the primary use of hydrocodone-homatropine?

Hydrocodone-homatropine is primarily used to treat cough and other respiratory symptoms by combining an opioid cough suppressant (hydrocodone) with an anticholinergic (homatropine) to reduce mucus production.

How has the FDA impacted the prescribing of hydrocodone-homatropine?

The FDA has issued safety communications that have led to a significant decline in prescriptions for hydrocodone cough and cold medications, especially in children and adolescents.

What are the main drivers of the opioids market growth?

The main drivers include the increasing geriatric population, rising approval rates for new opioid medications, and the growing need for pain management solutions.

What are the major restraints on the opioids market?

Major restraints include the side effects associated with opioid use, such as respiratory depression, and the risk of addiction and overdose, as well as regulatory measures to curb misuse.

How does the regulatory environment affect the pricing of hydrocodone-homatropine?

Regulatory changes and safety communications can influence pricing by affecting the availability and prescription rates of hydrocodone-homatropine, potentially leading to stable or modestly increasing prices.

Sources

1. JAMA Network Open: Prescriptions for Codeine or Hydrocodone Cough and Cold Medications Declined Substantially After FDA Safety Communications.
2. Health Canada: Summary Safety Review - Hydrocodone-containing products - Assessing the Risk of Serious Breathing Problems.
3. The Brainy Insights: Opioids Market Size, Share | CAGR of 3.7%.
4. DEA: Hydrocodone (Trade Names: Vicodin®, Lortab®, Lorcet-HD®).
5. GoodRx: Hydrocodone/Homatropine Prices, Coupons & Savings Tips.